RLV147, a potent resveratrol/ptersostilbene-analog, is currently in the discovery phase and targets KEAP1 (NRF2 agonist) as well as PDE4 and potentially SIRT1. RLV147 has high target potency and very low cytotoxicity which we anticipate will make it safe for long term use in the treatment of chronic inflammatory conditions and neuro-degenerative diseases.